55 kDa dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex Antibody

What is the 55 kDa dihydrolipoyllysine-residue acetyltransferase and its role in the pyruvate dehydrogenase complex?

The 55 kDa dihydrolipoyllysine-residue acetyltransferase (DLAT) is a critical component of the pyruvate dehydrogenase complex (PDC), a multienzyme complex that plays an essential role in energy metabolism by catalyzing the conversion of pyruvate to acetyl-CoA. DLAT constitutes the E2 component of the complex and contains a lysine residue (K245) that carries a covalently attached dihydrolipoic acid through an amide bond, forming dihydrolipoamide . This prosthetic group exists in both reduced and oxidized forms in the resting state, as confirmed by mass spectrometry analyses that identified predominantly non-acetylated forms of lipoyllysine with a minor amount in the acetylated form . Within the complex, DLAT functions to transfer the acetyl group from the first component (E1) to coenzyme A, forming acetyl-CoA that enters the Krebs cycle.

What experimental methods are recommended for detecting DLAT in biological samples?

For accurate detection of DLAT in biological samples, researchers should employ a multi-technique approach:

• Western Blotting: Anti-DLAT antibodies can be used to detect the protein in cell or tissue lysates. For optimal results, perform protein extraction under non-denaturing conditions if studying the intact complex, or denaturing conditions for specific component analysis. Sample preparation should include protease inhibitors to prevent degradation .

• Immunoprecipitation (IP): IP can be used to isolate DLAT from complex biological mixtures for downstream analysis. Researchers have successfully employed epitope-tagged versions (such as FLAG-tagged DLAT) in combination with size exclusion chromatography to study complex formation .

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of DLAT in serum samples, ELISA methods have been validated, showing diagnostic potential in clinical settings. In hepatocellular carcinoma research, serum DLAT has demonstrated significant diagnostic capability with AUC values of 0.905 for distinguishing HCC from healthy controls .

• Mass Spectrometry: For definitive identification and characterization of post-translational modifications, mass spectrometry remains the gold standard. Sample preparation typically involves gel excision, reduction, alkylation, and tryptic digestion followed by LC-MS/MS analysis .

How do different antibody formats affect experimental outcomes when studying DLAT?

The format and conjugation of anti-DLAT antibodies significantly impact experimental outcomes:

When selecting an antibody format, researchers should consider the specific experimental goals. For multiplexing studies, different conjugates may allow simultaneous detection of multiple targets. For studies requiring high sensitivity, HRP or fluorophore conjugates often provide advantages. The antibody's isotype and species origin should also be considered to avoid cross-reactivity issues, especially in complex samples or when using multiple antibodies simultaneously .

How does ionic strength affect PDC structure and DLAT accessibility for antibody recognition?

The pyruvate dehydrogenase complex displays remarkable structural plasticity that is highly dependent on ionic strength, which directly impacts antibody accessibility to DLAT epitopes. Under low ionic strength conditions (0 mM NaCl), the PDC predominantly exists as a megadalton-sized complex (≥2 MDa), while in physiological or higher ionic strength conditions (350 mM NaCl), it dissociates into sub-megadalton individual components . This salt-lability means that antibody recognition of DLAT can vary dramatically depending on buffer conditions.

Size exclusion chromatography (SEC) studies have revealed that in low salt conditions, purified PDC elutes with a higher molecular weight (≥2 MDa and ~1 MDa), while in higher salt conditions, DLAT components elute at volumes corresponding to much smaller sizes . Specifically, researchers have observed that:

• In mitochondria-enriched fractions under low salt conditions, PDC components peak at 8 ml elution volume (≥2 MDa) and 11-12 ml (~1 MDa)

• In higher salt conditions, components elute at 14-15 ml, corresponding to ~230-440 kDa proteins

For antibody-based detection, this structural variability necessitates careful optimization of buffer conditions. Researchers should consider performing parallel experiments under varying ionic strength conditions to ensure complete detection of all DLAT-containing species. Additionally, epitope accessibility may differ between the assembled complex and dissociated components, potentially requiring different antibody clones for comprehensive analysis .

What are the critical considerations for distinguishing post-translational modifications of DLAT using antibodies?

Distinguishing between different post-translational modifications (PTMs) of DLAT requires careful antibody selection and validation:

How can researchers optimize immunoprecipitation protocols for studying DLAT interactions within the PDC?

Optimizing immunoprecipitation (IP) protocols for DLAT requires addressing the complex's unique structural properties:

• Buffer Selection: Given the salt-lability of the PDC, buffer ionic strength critically determines whether you capture the intact complex or individual components. For studying DLAT within the intact complex, use low ionic strength buffers (0 mM NaCl); for studying individual components, use physiological or higher ionic strength (350 mM NaCl) .

• Epitope Tagging Strategy: Studies have successfully employed epitope-tagged versions (3xHA, V5, 5xFLAG) of PDC components for efficient IP. When investigating DLAT (Pdb1 in yeast), 3xHA tagging has been validated for successful pulldown .

• Validation by Size Analysis: Following IP, size exclusion chromatography can validate whether the captured material represents intact complex or dissociated components. The elution profiles should be compared to those obtained from extracts - with expected peaks at 8 ml for several MDa (≥2 MDa) complexes and at 11-12 ml for ~1 MDa proteins under low salt conditions .

• Crosslinking Consideration: For capturing transient interactions, mild crosslinking with agents like disuccinimidyl suberate (DSS) or formaldehyde before cell lysis can preserve interactions that might otherwise be lost during purification.

• Sequential IP: To analyze specific subcomplexes, sequential IP using antibodies against different components can isolate defined PDC subassemblies containing DLAT.

What is the relationship between DLAT expression and disease states, particularly in cancer research?

DLAT expression has emerged as a significant biomarker in cancer research, particularly in hepatocellular carcinoma (HCC):

• Expression Profile: DLAT is upregulated in HCC tissues compared to non-cancerous liver tissues, as demonstrated through comprehensive bioinformatic analyses and validated by quantitative PCR and Western blotting .

• Diagnostic Potential: Serum DLAT shows remarkable diagnostic capability for HCC detection:

  • The area under the ROC curve (AUC) for distinguishing HCC from healthy controls is 0.905

  • For distinguishing HCC from high-risk individuals: AUC of 0.754

  • For distinguishing HCC from non-HCC cohorts: AUC of 0.831

• Complementary Biomarker: Combining DLAT with alpha-fetoprotein (AFP) significantly improves diagnostic accuracy, with AUCs of 0.957, 0.819, 0.773, and 0.887 for respective comparisons. Most notably, serum DLAT was positive in 71.4% of AFP-negative HCC patients, suggesting its value as a complementary biomarker .

• Regulatory Mechanisms: DLAT expression is regulated by multiple factors including:

  • microRNA regulation: hsa-miR-122-5p (transfection of this miRNA mimic downregulates DLAT expression)

  • Transcription factors: ZNF148, MAZ, and ZBTB12

  • Epigenetic regulation: Increased DLAT promoter methylation has been observed

• Immunological Correlation: DLAT expression has been identified as an independent risk factor associated with immune cell infiltration in HCC, suggesting a potential role in tumor immune microenvironment modulation .

What emerging applications exist for anti-DLAT antibodies in studying metabolic reprogramming?

Emerging applications for anti-DLAT antibodies in metabolic reprogramming research include:

• Nuclear PDC Localization: Recent reports have demonstrated the unexpected presence of PDC in the nucleus of mammalian cells, which is a non-canonical location for this traditionally mitochondrial complex . Anti-DLAT antibodies can help track this translocation and study its functional significance in histone acetylation and gene regulation.

• PDC Structural Dynamics: The variable structure of PDC under different conditions suggests a mechanism for activity regulation. Anti-DLAT antibodies can be used to track structural reorganization in response to metabolic cues by employing techniques like proximity ligation assays or FRET-based approaches to monitor component interactions .

• Post-translational Modification Mapping: Beyond acetylation, DLAT undergoes multiple PTMs including succination. Anti-DLAT antibodies combined with specific PTM antibodies can map modification patterns under various metabolic states or disease conditions .

• Metabolic Flux Analysis: Antibodies against DLAT can be employed in immunocapture approaches to isolate active PDC from cells under different metabolic conditions, followed by activity assays to correlate structural changes with function.